- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02809001
The Effects of Autologous Fat Transfer on Preventing Expanded Skin From Expansion Failure
Studieoversikt
Detaljert beskrivelse
The repair of skin defects is a common problem for reconstructive surgeons.Soft tissue expansion is a widely used technique for the repair of skin defects. Early expansion-related complications such as skin thinning, telangiectasia, and striae may result in expansion failure and ultimately jeopardize final outcome. In the past years, discontinuation of the expansion procedure was the only therapeutic option, when early alarm signs such as semitransparent appearance and telangiectasia of the expanded skin were encountered. We aimed to overcome these complications by therapeutic fat grafting to prevent skin necrosis and enable continuation of the expansion procedure.
Patients undergoing soft tissue expansion treatment for resurfacing skin lesions including scars and nevi that required therapeutic intervention due to early complication signs were included in this study. Patients were randomly divided into treatment group using autologous fat grafting and control group with discontinued expansion and expectant management. The treatment group received autologous fat transfer to the expanded skin.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Shanghai, Kina
- Shanghai Ninth People's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Expanding skin donor site at the face, neck, anterior chest wall, abdominal wall or back;
- Implanted silicone expander of 50 to 800 ml in size;
- History of deterioration in the expanded skin texture that did not improve after the inflation procedure was suspended for more than 2 weeks;
- Persistent high level of expander internal pressure;
- Need for further skin expansion;
Exclusion Criteria:
- Evidence of infection, ischemia, ulcer or other pathological changes within the targeting area which defined as not suitable for expansion; or history of delayed healing, radiational therapy;
- Rupture of expanded skin, expander exposure;
- Significant renal, cardiovascular, hepatic and psychiatric diseases;
- Significant medical diseases or infection (including but not limited to the carrier of hepatitis B virus or HIV);
- BMI less than 17 or insufficient subcutaneous fat;
- History of any hematological disease, including leukopenia , thrombocytopenia, or thrombocytosis;
- History of allogenic bone marrow transplantation;
- Pregnant or lactating woman;
- Long history of smoking;
- Evidence of malignant diseases or unwillingness to participate
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental: Fat grafting
Autologous fat graft transplantation subdermally to expanded skin.
|
In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline.
Patients will receive autologous fat graft transplantation subdermally to expanded skin.
|
|
Ingen inngripen: Control
Expansion was discontinued until the early signs of complication disappeared.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To Measure the Change in Expansion Volume
Tidsramme: Change from baseline volume at 12 weeks
|
Record the volume(ml) of each expander
|
Change from baseline volume at 12 weeks
|
|
To Measure the Change in Skin Thickness
Tidsramme: Change from baseline skin thickness at 12 weeks
|
Record the thickness of the expanded skin(cm) by ultrasound scanning
|
Change from baseline skin thickness at 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To Measure the Texture of Expanded Flap with VISIA scanner
Tidsramme: baseline and 12 weeks post treatment
|
Evaluate skin texture with VISIA scanner and compare the characteristics
|
baseline and 12 weeks post treatment
|
|
Occurence of Major Adverse Events
Tidsramme: Up to approximately 12 weeks after study start
|
Including expanded flap ischaemia, necrosis, fluidify, infection, and all other adverse events
|
Up to approximately 12 weeks after study start
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- Shanghai9PH
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nevus
-
Massachusetts General HospitalHar ikke rekruttert ennåMedfødt melanocytisk Nevus
-
Mahidol UniversityUkjentFokus på laserbehandling av Nevus of Ota hos thailandske pasienterThailand
-
University Hospital, Basel, SwitzerlandFullført
-
Istanbul Training and Research HospitalFullførtNevus, pigmentertTyrkia
-
Manchester University NHS Foundation TrustNational Institute for Health Research, United KingdomFullført
-
Central Hospital, Nancy, FranceAssistance Publique Hopitaux De Marseille; Centre Hospitalier Universitaire... og andre samarbeidspartnerePåmelding etter invitasjonPsykologi, sosial | Foreldre | Medfødt melanocytisk Nevus | Medfødt melanocytisk NeviFrankrike
-
Xijing HospitalHar ikke rekruttert ennå
-
University of California, IrvineBeckman Laser Institute University of California IrvineTilbaketrukketMelanocytisk NevusForente stater
-
National Cancer Institute (NCI)FullførtMelanocytisk Nevi | Ervervet Melanocytic Nevi | Primært hudmelanomForente stater
-
MelanomaPRO, RussiaPrivolzhsky Research Medical UniversityRekrutteringNevus | Nevus, pigmentert | Melanom (hud) | Basalcellekarsinom | Plateepitelkarsinom | Bowens sykdom | Nevus, Spitz | Melanom in situ | Nevus Halo | FlekkpigmentertDen russiske føderasjonen
Kliniske studier på Fat grafting
-
University of PittsburghArmed Forces Institute of Regenerative MedicineRekruttering
-
NYU Langone HealthNational Institute on Deafness and Other Communication Disorders (NIDCD)Rekruttering
-
Midwest Heart & Vascular SpecialistsRekrutteringAL Amyloidose | Amyloid | Hjerte amyloidose | Amyloidose Hjerte | Systemisk amyloidose | ATTR Amyloidosis villtype | Infiltrativ kardiomyopati, amyloidForente stater
-
Ryazan State Medical UniversityRekrutteringKritisk iskemi i nedre ekstremiteterDen russiske føderasjonen
-
Armed Forces Institute of Cardiology, PakistanFullført
-
University Medical Center GroningenUkjentKoronar bypass | Kognitiv dysfunksjonNederland
-
University of GlasgowUniversitaire Ziekenhuizen KU Leuven; Campus Bio-Medico University; Thorax... og andre samarbeidspartnereTilbaketrukketKoronararteriesykdom | Kirurgisk sårinfeksjonStorbritannia, Belgia, Italia, Nederland
-
EMO Biomedicine CorporationFar Eastern Memorial HospitalFullført
-
University of PennsylvaniaNational Center for Advancing Translational Sciences (NCATS)FullførtKardiovaskulære sykdommer | Sjokk | Kritisk sykdomForente stater
-
University of Sao Paulo General HospitalHospital Israelita Albert Einstein; Instituto Dante Pazzanese de Cardiologia og andre samarbeidspartnereFullførtHjertekirurgiske prosedyrerBrasil